Shield Therapeutics (LON:STX) Shares Cross Above Fifty Day Moving Average - Should You Sell?

Key Points

• Shares of Shield Therapeutics briefly crossed above their 50-day moving average intraday (50-day MA GBX 8.83; intraday high GBX 9) but last traded at GBX 8.70 on volume 2,435,412.
• The stock remains below its 200-day MA (GBX 9.20) and shows weak profitability and small size (market cap £95.05m, P/E -4.45), with balance-sheet ratios including debt-to-equity -199.87, quick ratio 2.16 and current ratio 0.90.
• Shield is a commercial-stage specialty pharmaceutical company marketing Accrufer/Feraccru (ferric maltol), launched in the U.S. under an exclusive commercial agreement with Viatris and licensed to partners outside the U.S.

Shield Therapeutics plc (LON:STX - )'s share price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of GBX 8.83 and traded as high as GBX 9. Shield Therapeutics shares last traded at GBX 8.70, with a volume of 2,435,412 shares.

Shield Therapeutics Stock Performance

The firm's 50-day moving average price is GBX 8.83 and its two-hundred day moving average price is GBX 9.20. The company has a debt-to-equity ratio of -199.87, a quick ratio of 2.16 and a current ratio of 0.90. The stock has a market cap of £95.05 million, a price-to-earnings ratio of -4.45 and a beta of 1.92.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.